BDSX Biodesix, Inc.
$21.95▲ +3.25%
Healthcare
Other
Volume 141.7K
Avg Volume (10D) 74.7K
Key Metrics & Fundamentals
Market Cap
$231.60M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.26 - 31.97
% vs 50 MA
-17.11%
% vs 200 MA
18.97%
RSI-14
35.4
MACD Histogram
-0.4300
Beta (1Y vs SPY)
0.94
Free Cash Flow
-$1.82M
Gross Rev
$26.86M
Gross Profit
$22.04M
EBITDA
-$3.87M
COGS
$4.82M
Operating Exp
$27.42M
Operating Income
-$5.38M
EBIT
-$5.38M
Pretax Income
-$7.27M
Net Income
-$7.27M
EPS (Diluted)
-0.71
Price & Volume History
Loading chart…
Recent News
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
GlobeNewswire · Oct 22, 2026 6:00 AM ET
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
GlobeNewswire · Oct 19, 2026 4:01 PM ET
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
GlobeNewswire · Oct 19, 2026 6:00 AM ET
Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth
Simply Wall St. · Oct 14, 2026 9:15 PM ET
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
GlobeNewswire · Oct 13, 2026 6:00 AM ET
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
Zacks · Oct 5, 2026 7:09 AM ET
Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative
Simply Wall St. · Sep 28, 2026 9:09 PM ET
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
Zacks · Sep 28, 2026 10:03 AM ET
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
InvestorsHub · Sep 24, 2026 6:34 AM ET
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
GlobeNewswire · Sep 24, 2026 6:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See BDSX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.